Analysts Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Price Target at $25.71

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) have been given an average recommendation of “Moderate Buy” by the nine analysts that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $26.1429.

Several brokerages recently commented on DAWN. Wedbush raised their target price on Day One Biopharmaceuticals from $29.00 to $30.00 and gave the stock an “outperform” rating in a research report on Wednesday. Needham & Company LLC reduced their price objective on shares of Day One Biopharmaceuticals from $18.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday. Zacks Research upgraded shares of Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 26th. TD Cowen began coverage on shares of Day One Biopharmaceuticals in a research report on Tuesday, January 13th. They issued a “buy” rating and a $34.00 price target for the company. Finally, Piper Sandler lifted their price objective on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th.

Insiders Place Their Bets

In related news, CFO Charles N. York II sold 6,065 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $70,354.00. Following the completion of the sale, the chief financial officer owned 312,025 shares in the company, valued at $3,619,490. This trade represents a 1.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Jeremy Bender sold 15,459 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $179,324.40. Following the completion of the transaction, the chief executive officer owned 204,603 shares in the company, valued at approximately $2,373,394.80. This trade represents a 7.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 36,461 shares of company stock worth $422,948 in the last quarter. 6.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Institutional investors have recently bought and sold shares of the business. Federated Hermes Inc. bought a new stake in shares of Day One Biopharmaceuticals during the third quarter worth $39,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Day One Biopharmaceuticals by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company’s stock worth $46,000 after buying an additional 1,029 shares in the last quarter. Ameritas Investment Partners Inc. grew its holdings in Day One Biopharmaceuticals by 44.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock worth $48,000 after acquiring an additional 2,264 shares during the last quarter. Quarry LP bought a new stake in Day One Biopharmaceuticals during the 3rd quarter worth about $49,000. Finally, Entropy Technologies LP acquired a new stake in Day One Biopharmaceuticals in the 2nd quarter valued at about $67,000. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Stock Performance

Shares of DAWN opened at $10.93 on Friday. The company has a 50-day simple moving average of $10.67 and a 200-day simple moving average of $8.76. Day One Biopharmaceuticals has a 52 week low of $5.64 and a 52 week high of $13.20. The firm has a market capitalization of $1.12 billion, a P/E ratio of -10.61 and a beta of -1.26.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.04). Day One Biopharmaceuticals had a negative net margin of 67.85% and a negative return on equity of 23.14%. The firm had revenue of $53.72 million for the quarter, compared to the consensus estimate of $49.81 million. As a group, equities analysts forecast that Day One Biopharmaceuticals will post -0.72 earnings per share for the current year.

Day One Biopharmaceuticals News Roundup

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Q4 revenue beat and product momentum: Day One reported Q4 net product revenue that topped estimates and highlighted OJEMDA™ momentum and record revenue growth for 2025. Article Title
• Positive Sentiment: Company reaffirmed 2026 outlook and guidance: Day One reiterated 2026 U.S. net product revenue guidance of $225–$250M and disclosed the January acquisition of Mersana to expand its pipeline. Article Title
• Positive Sentiment: Analyst uplift from Wedbush: Wedbush raised its price target sharply to $30 and keeps an outperform rating, signaling at least one broker sees substantial upside vs. the current price. Article Title
• Neutral Sentiment: Other analysts trimmed targets but kept buy ratings: Needham cut its target to $17 and HC Wainwright trimmed to $22, yet both maintain positive ratings — a mixed signal on near-term valuation. Article Title
• Neutral Sentiment: Full earnings materials and transcripts available: The earnings slide deck and call transcript are posted for investors to review management commentary and guidance details. Article Title
• Neutral Sentiment: Short-interest data unclear: February short-interest reporting here shows effectively 0 shares (data appears inconsistent/NaN); no clear short-squeeze signal from the published short-interest figures.
• Negative Sentiment: EPS miss pressures sentiment: Reported EPS came in at ($0.21), missing the consensus of ($0.17); that earnings shortfall helps explain the stock selling off despite the revenue beat. Article Title

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.